Please login to the form below

Not currently logged in

Merck & Co appoints Frank Clyburn as president, human health

Clyburn joined the company in 2008, most recently serving as chief commercial officer for human health

Merck & Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health.

In a statement, Merck & Co announced that Clyburn will take on the role effective immediately, and will lead all human health marketing and commercial operations.

He will be responsible for the company’s human health profit and loss (P&L) globally, reporting to Merck’s current chief executive officer Kenneth Frazier.

In January 2019, Clyburn became chief commercial officer for human health at Merck & Co.

Prior to this, he was president of the company’s global oncology business.

Clyburn joined Merck & Co in 2008 and during his time with the company, he has had responsibility for various global pharmaceutical franchises.

“I have tremendous respect for Frank’s strategic and operational excellence, and believe he is the perfect person to lead our ongoing success in human health,” said Robert Davis, executive vice president, global services and chief financial officer of Merck & Co.

“Frank’s leadership in rapidly expanding our oncology footprint and accelerating the growth of that business is unparalleled in our industry, exceeded only by his relentless dedication to helping patients. I look forward to continuing to work with him as we advance Merck’s mission to save and improve lives,” he added.

Article by
Lucy Parsons

19th March 2021

From: Research


Subscribe to our email news alerts


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story
Working together to achieve better patient pathways
Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.
How design can lead improvement within Pharma...